The US Food and Drug Administration (FDA) has accepted and offered priority review for a new supplemental biologics license application for United States-based Merck's Keytruda intended for the treatment for earlier treated patients with advanced hepatocellular carcinoma, it was reported yesterday.
The new supplemental biologics license application is based on data from the Phase two KEYNOTE-224 trial, which were recently presented at the 2018 American Society of Clinical Oncology Annual Meeting and published simultaneously in The Lancet Oncology.
The company's broad immuno-oncology clinical development program includes more than 10 Merck-sponsored studies investigating the product in gastrointestinal cancers, including hepatocellular carcinoma. In addition to KEYNOTE-224, the company has two ongoing pivotal Phase three studies, KEYNOTE-240 and KEYNOTE-394, assessing the product as monotherapy in second-line hepatocellular carcinoma, as well as ongoing trials investigating KEYTRUDA in combination with other treatments including LENVIMA.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT